Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

IDH2 R172 mutation is associated with improved survival in IDH-mutated AML/MDS patients undergoing allogeneic stem cell transplantation: A geth-TC multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAna Pérez GonzálezHebron UniversityMGManuel GuerreiroEuropean Organisation for Research and Treatment of CancerMMM. MontanerHospital Universitari i Politècnic La Fe

Discussion

Loading...

Member takes

Overview

Multicenter analysis shows IDH2 R172 mutation enhances overall and progression-free survival in AML patients after allogeneic stem cell transplantation, indicating important clinical implications.

Key Points

  • To evaluate the prognostic impact of IDH2 R172 mutation on survival outcomes in AML/MDS patients undergoing allogeneic stem cell transplantation.
  • Retrospective multicenter study across nine institutions.
  • Inclusions were AML/MDS patients diagnosed according to WHO 2016 criteria with IDH mutations confirmed by sequencing.
  • Primary endpoint was overall survival (OS), with secondary endpoints including progression-free survival (PFS) and relapse incidence.
  • 1-year overall survival for IDH2 R172 mutation was 93% compared to 74% for other mutations (p=0.05).
  • IDH2 R172 was associated with a lower relapse incidence of 0% versus 14% for other subtypes (p<0.001).
  • 1-year progression-free survival was 93% for IDH2 R172 versus 74% for others (p=0.06).

Cite This Study

González et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8b9https://doi.org/10.1182/blood-2025-6082
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Isocitrate Dehydrogenase (IDH) 1 and 2 Mutations Predicts Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation: a study of the ALWP of the EBMT2024
  2. 2Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML2025
  3. 3IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies2025
  4. 4Mutations in IDH1 and IDH2 portend a poor prognosis in adult patients with acute lymphoblastic leukemia2025
  5. 5The synonymous IDH1 p.Gly105Gly (rs11554137) variant associates with AML post-transplant relapse via aberrant signal transduction pathways2025